-
1
-
-
0020559574
-
A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
-
Bast RC Jr., Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309(15):883-7.
-
(1983)
N Engl J Med
, vol.309
, Issue.15
, pp. 883-887
-
-
Bast Jr., R.C.1
Klug, T.L.2
St. John, E.3
Jenison, E.4
Niloff, J.M.5
Lazarus, H.6
-
2
-
-
0022596973
-
Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer
-
Einhorn N, Bast RC Jr., Knapp RC, Tjernberg B, Zurawski VR Jr. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986;67(3):414-6.
-
(1986)
Obstet Gynecol
, vol.67
, Issue.3
, pp. 414-416
-
-
Einhorn, N.1
Bast Jr., R.C.2
Knapp, R.C.3
Tjernberg, B.4
Zurawski Jr., V.R.5
-
3
-
-
0023929166
-
Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses
-
Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988;72(1):23-7.
-
(1988)
Obstet Gynecol
, vol.72
, Issue.1
, pp. 23-27
-
-
Chen, D.X.1
Schwartz, P.E.2
Li, X.G.3
Yang, Z.4
-
4
-
-
0029862921
-
CA 125: An evolving role in the management of ovarian cancer
-
Markman M. CA 125: an evolving role in the management of ovarian cancer [editorial]. J Clin Oncol 1996;14(5):1411-2.
-
(1996)
J Clin Oncol
, vol.14
, Issue.5
, pp. 1411-1412
-
-
Markman, M.1
-
5
-
-
0028236178
-
Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma
-
Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. [review]. Obstet Gynecol 1994;84(1):12-6.
-
(1994)
Obstet Gynecol
, vol.84
, Issue.1
, pp. 12-16
-
-
Rose, P.G.1
Sommers, R.M.2
Reale, F.R.3
Hunter, R.E.4
Fournier, L.5
Nelson, B.E.6
-
6
-
-
0024322579
-
CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma
-
Tseng PC, Sprance HE, Carcangiu ML, Chambers JT, Schwartz PE. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma. Obstet Gynecol 1989;74(3 Pt 1):384-7.
-
(1989)
Obstet Gynecol
, vol.74
, Issue.3 PART 1
, pp. 384-387
-
-
Tseng, P.C.1
Sprance, H.E.2
Carcangiu, M.L.3
Chambers, J.T.4
Schwartz, P.E.5
-
7
-
-
0027733830
-
Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC)
-
Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol 1993;51(3):383-9.
-
(1993)
Gynecol Oncol
, vol.51
, Issue.3
, pp. 383-389
-
-
Price, F.V.1
Chambers, S.K.2
Carcangiu, M.L.3
Kohorn, E.I.4
Schwartz, P.E.5
Chambers, J.T.6
-
8
-
-
10244261646
-
Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers
-
Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88(20):1456-66.
-
(1996)
J Natl Cancer Inst
, vol.88
, Issue.20
, pp. 1456-1466
-
-
Hayes, D.F.1
Bast, R.C.2
Desch, C.E.3
Fritsche, H.4
Kemeny, N.E.5
Jessup, J.M.6
-
9
-
-
0023938229
-
The role of CA 125 in the evaluation of palpable or enlarged postmenopausal ovaries
-
Schwartz PE. The role of CA 125 in the evaluation of palpable or enlarged postmenopausal ovaries. Am J Obstet Gynecol 1988;158(5):1072-3.
-
(1988)
Am J Obstet Gynecol
, vol.158
, Issue.5
, pp. 1072-1073
-
-
Schwartz, P.E.1
-
10
-
-
0029961618
-
Denning response of ovarian carcinoma to initial chemotherapy according to serum CA 125
-
Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, et al. Denning response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14(5):1545-51.
-
(1996)
J Clin Oncol
, vol.14
, Issue.5
, pp. 1545-1551
-
-
Rustin, G.J.1
Nelstrop, A.E.2
McClean, P.3
Brady, M.F.4
McGuire, W.P.5
-
11
-
-
2642617646
-
Preoperative CA 125: Assessment of role and significance in uterine cancer
-
Sood AK, Buller RE, Burger R, Dawson J, Sorosky JI, Berman M. Preoperative CA 125: assessment of role and significance in uterine cancer. Gynecol Oncol 1997;64(2):308.
-
(1997)
Gynecol Oncol
, vol.64
, Issue.2
, pp. 308
-
-
Sood, A.K.1
Buller, R.E.2
Burger, R.3
Dawson, J.4
Sorosky, J.I.5
Berman, M.6
-
12
-
-
0026476737
-
False-positive elevation of CA 125 in papillary serous carcinoma of the endometrium treated with postoperative whole abdominal radiation
-
Rose PG, Nelson BE, Reale FR. False-positive elevation of CA 125 in papillary serous carcinoma of the endometrium treated with postoperative whole abdominal radiation. Gynecol Oncol 1992;47(1):127-9.
-
(1992)
Gynecol Oncol
, vol.47
, Issue.1
, pp. 127-129
-
-
Rose, P.G.1
Nelson, B.E.2
Reale, F.R.3
|